Bevacizumab in combination with sequential high-dose chemotherapy in solid cancer, a feasibility study

[1]  P. Wen,et al.  Neurological adverse effects caused by cytotoxic and targeted therapies , 2009, Nature Reviews Clinical Oncology.

[2]  L. Qin,et al.  Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Patrick Schöffski,et al.  Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Verweij.  Soft tissue sarcoma trials: one size no longer fits all. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  G. Capellá,et al.  Sunitinib Inhibits Tumor Growth and Synergizes with Cisplatin in Orthotopic Models of Cisplatin-Sensitive and Cisplatin-Resistant Human Testicular Germ Cell Tumors , 2009, Clinical Cancer Research.

[6]  A. Horwich,et al.  Testicular seminoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  J. J. de la Cruz,et al.  Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  G. Demetri,et al.  Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M. Blackstein,et al.  Dose‐intensive chemotherapy with growth factor or autologous bone marrow/stem cell transplant support in first‐line treatment of advanced or metastatic adult soft tissue sarcoma , 2008, Cancer.

[10]  S. Fosså,et al.  European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. , 2008, European urology.

[11]  D. Schiff,et al.  Bevacizumab in combination with irinotecan for patients with recurrent glioblastoma multiforme , 2008, Nature Clinical Practice Oncology.

[12]  John Sampson,et al.  Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  W. Hiddemann,et al.  Efficacy of Consolidation High-Dose Chemotherapy with Ifosfamide, Carboplatin and Etoposide (HD-ICE) Followed by Autologous Peripheral Blood Stem Cell Rescue in Chemosensitive Patients with Metastatic Soft Tissue Sarcomas , 2007, Oncology.

[14]  J. Ledermann,et al.  High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  D. Hicklin,et al.  Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: implications for tumor growth, metastasis, and chemoresistance. , 2006, Cancer research.

[16]  D. Goldenberg,et al.  Targeted Therapy of Cancer: New Prospects for Antibodies and Immunoconjugates , 2006, CA: a cancer journal for clinicians.

[17]  J. Hildebrand.  Neurological complications of cancer chemotherapy , 2006, Current opinion in oncology.

[18]  B. Lane,et al.  Reversible posterior leukoencephalopathy syndrome and bevacizumab. , 2006, The New England journal of medicine.

[19]  W. Voigt,et al.  Bevacizumab plus high-dose ifosfamide, etoposide and carboplatin (HD-ICE) as third-line salvage chemotherapy induced an unexpected dramatic response in highly platinum refractory germ-cell cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  R. Maki,et al.  Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  J. Picus,et al.  Evaluating Risk Factors for the Development of Ifosfamide Encephalopathy , 2005, American journal of clinical oncology.

[22]  H. Goldschmidt,et al.  High-dose chemotherapy with autologous peripheral blood stem cell transplantation for bone and soft-tissue sarcomas , 2004, Bone Marrow Transplantation.

[23]  B Landuyt,et al.  Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11 , 2003, British Journal of Cancer.

[24]  B. Eisenberg,et al.  Vascular Endothelial Growth Factor and Soft Tissue Sarcomas: Tumor Expression Correlates With Grade , 2001, Annals of Surgical Oncology.

[25]  J. Blay,et al.  High-dose chemotherapy with autologous hematopoietic stem-cell transplantation for advanced soft tissue sarcoma in adults. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  S. Akiba,et al.  Expression of vascular endothelial growth factor in patients with testicular germ cell tumors as an indicator of metastatic disease , 1999, Cancer.

[27]  S. Shord,et al.  Encephalopathy after High-Dose Ifosfamide , 2008, Drug safety.

[28]  S. Fosså,et al.  European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. , 2008, European urology.

[29]  [Recommendations for diagnosis, treatment and follow-up of the Trypanosoma cruzi: human immunodeficiency virus co-infection]. , 2006, Revista da Sociedade Brasileira de Medicina Tropical.

[30]  Ma Dong,et al.  Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .

[31]  Z. Hua.  Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer , 2006 .